All In Biotech

Drug Trial Radar · NCT07282873

Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors

A Phase I/II, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of the TEAD Inhibitor TYK-01054 Capsules in Patients With Locally Advanced or Metastatic Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

219

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Jan 2028

Study completion Jun 2029

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors

Conditions

  • Solid Tumor Malignancies
  • Malignant Mesothelioma (MM)

Interventions

  • TYK-01054Drug

    TKY-01054 will be administered orally at a starting dose of 25 mg in 21-day cycles. If well tolerated, dose expansion will proceed in the recommended dose for expansion (RDE) and RDE-1 until the recommended Phase II dose (RP2D) is determined.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting ToxicityTime frame: Up to approximately 28 days
  2. Maximum tolerated dose(MTD)Time frame: Through the Dose Escalation phase, approximately 12 months
  3. Number of participants who experience one or more adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
  4. Recommended Dose for Expansion(RDE)Time frame: Through the Dose Escalation Phase, approximately 24 months
  5. Recommended Phase 2 Dose(RP2D)Time frame: Within 28 days of the last patient dosed in the Dose Optimization stage

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.